| factor Inv | A factor that determines certain of the allotypes of human immunoglobulins; found on the kappa chains of IgG, IgA, IgM, and Bence Jones protein. (05 Mar 2000) |
|---|---|
| factor IV | In the clotting of blood, calcium ions. (05 Mar 2000) |
| factor ix | <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b). Chemical name: Blood-coagulation factor IX (12 Dec 1998) |
| factor ix assay | A test used to measure the activity of a blood clotting factor IX (Christmas factor). This test may be used to evaluate excessive bleeding. Abnormally low factor IX assays may be seen in the following conditions: congenital deficiency of factor IX, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration. (27 Sep 1997) |
| factor ix deficiency | A form of haemophilia in males that results from a deficiency of clotting factor IX, transmitted as a X-linked trait. Symptoms include easy bruising, nosebleeds, bleeding gums and bleeding into muscle tissue (haematoma) or a joint space (haemarthrosis). Treatment includes the infusion of factor IX concentrates to normalize blood coagulation. (27 Sep 1997) |
| factor ixa | <enzyme> Activated form of factor ix. This activation can take place via the intrinsic pathway by the action of factor xia and calcium, or via the extrinsic pathway by the action of factor viia, thromboplastin, and calcium. Factor ixa serves to activate factor x to xa by cleaving the arginyl-leucine peptide bond in factor x. Registry number: EC 3.4.21.22 (12 Dec 1998) |
| factor P | A chemical (postulated by T. Lewis), formed in ischemic skeletal or cardiac muscle, held to be responsible for the pain of intermittent claudication and angina pectoris. (05 Mar 2000) |
| factor v | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| factor v assay | A test used to measure the activity of a blood clotting factor V. This test may be used to evaluate excessive bleeding. Abnormally low factor V assays may be seen in the following conditions: congenital deficiency of factor V, DIC, heparin administration, cirrhosis and primary fibrinolysis. (27 Sep 1997) |
| factor v deficiency | An inherited disorder that results in abnormal blood clotting due to the deficiency of factor V, one of 20 plasma proteins responsible for the maintenance of normal blood clotting. Symptoms include excessive bleeding, bleeding gums, nosebleeds, easy bruising, excessive menstrual bleeding and bleeding into muscle tissue (haematoma) or a joint space (haemarthrosis). Treatment includes the infusion of fresh frozen plasma to restore deficient factor V. (27 Sep 1997) |
| factor V1a | The hexa-amide of cobyrinic acid; a part of the vitamin B12 structure. Synonym: cobyrinamide, cobyrinic hexa-amide, factor V1a. (05 Mar 2000) |
| factor va | <chemical> Activated form of factor v. It is an essential cofactor for the activation of prothrombin catalyzed by factor xa. Chemical name: Blood-coagulation factor Va (12 Dec 1998) |
| factor vii | <chemical> Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor viia in the extrinsic pathway of blood coagulation. The activated form then catalyses the activation of factor x to factor xa. Chemical name: Blood-coagulation factor VII (12 Dec 1998) |
| factor vii assay | A test used to measure the activity of a blood clotting factor VII. This test may be used to evaluate excessive bleeding. Abnormally low factor VII assays may be seen in the following conditions: congenital deficiency of factor VII, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration. (27 Sep 1997) |
| factor vii deficiency | An inherited disorder that causes abnormal blood clotting due to the congenital absence of one of the 20 different plasma proteins involved in the coagulation process. Symptoms include bleeding of the gums, nosebleeds, easy bruising, bleeding in muscles or joints and excessive menstrual bleeding. Treatment includes the administration of plasma concentrates of factor VII (extrinsic factor). (27 Sep 1997) |
| antihemorrhagic factor | <biochemistry> A fat soluble vitamin that plays an important role in blood clotting. (27 Sep 1997) |
|---|---|
| antineuritic factor | A member of the water-soluble B vitamin group, necessary for energy production and carbohydrate metabolism. Deficiency is known as beriberi. (27 Sep 1997) |
| antinuclear factor | A factor, usually antibodies, present in serum with strong affinity for nuclei and detected by fluorescent antibody technique; present in lupus erythematosus, rheumatic arthritis, and certain other autoimmune conditions; may also be present at lower levels in normal individuals. (05 Mar 2000) |
| antipellagra factor | A precursor of NAD, that is a product of the oxidation of nicotine. (18 Nov 1997) |
| antipernicious anaemia factor | <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism. (27 Sep 1997) |
| antisterility factor | <biochemistry> Functions as an antioxidant, binds oxygen free radicals that can cause tissue damage, may also play a protective role in the coronary arteries from the damaging effects of cholesterol. (27 Sep 1997) |
| antitermination factor | <molecular biology> A gene regulatory protein that blocks signals for the transcription process to stop as a form of regulatory control over whatever the gene being transcribed is coding for. (13 Jan 1998) |
| atrial natriuretic factor | <chemical> A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight peptides derived from a common precursor and secreted by the heart atria. All these peptides share a sequence of about 20 amino acids. Chemical name: Atriopeptin (12 Dec 1998) |
| attenuation factor | <radiobiology> A measure of the opacity of a layer of material for radiation transversing it, the ratio of the incident intensity to the transmitted intensity. It is equal to Io/I, where Io and I are the intensities of the incident and emergent radiation, respectively. In the usual sense of exponential absorption (I = Ioe- m x), the attenuation factor is e- m x, where x is the thickness of the material and m is the absorption coefficient. (16 Dec 1997) |
| autocrine motility factor | A member of the class of cytokines secreted by tumour cells. It elicits increases in cell motility and phosphoinositide metabolism in the secreting or producing cell via a pertussis toxin-sensitive g-protein signal transduction pathway. The factor has also been used as a marker for bladder cancer. (12 Dec 1998) |
| B-cell differentiating factor | <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells. Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages. Acronym: IL-4 (12 Dec 1998) |
| B-cell stimulatory factor 2 | <cytokine> A cytokine that stimulates the growth and differentiation of human B-cells and is also a growth factor for hybridomas and plasmacytomas. It is produced by many different cells including T-cells, monocytes, and fibroblasts. A single chain 25 kD cytokine originally described as a pre B-cell growth factor, now known to have effects on a number of other cells including T-cells which are also stimulated to proliferate. An inducer of acute phase proteins and a colony-stimulating factor acting on mouse bone marrow. Acronym: IL-6 (12 Dec 1998) |
| bifidus factor | An unidentified substance associated with Lactobacillus bifidus subsp. Pennsylvanicus, present in mammalian milk. (05 Mar 2000) |
| bioaccumulation factor | Concentration of a chemical in living tissue divided by its concentration in the animal's diet. (09 Oct 1997) |
| bioconcentration factor | Concentration of a chemical in an organism divided by its concentration in the test solution or environment (for example, concentration in fish divided by concentration in water). (09 Oct 1997) |